Equities Analysts Offer Predictions for Exagen Q1 Earnings

Exagen Inc. (NASDAQ:XGN) – Research analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for Exagen in a research report issued on Wednesday, March 12th. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.24). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

XGN has been the topic of a number of other research reports. Canaccord Genuity Group increased their target price on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price target on shares of Exagen in a research note on Monday, January 13th.

Exagen Stock Performance

XGN stock opened at $3.56 on Friday. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. The business’s fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $3.57. Exagen has a twelve month low of $1.30 and a twelve month high of $6.22. The firm has a market cap of $62.79 million, a price-to-earnings ratio of -3.79 and a beta of 1.40.

Hedge Funds Weigh In On Exagen

Several institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank purchased a new position in shares of Exagen during the fourth quarter valued at $3,655,000. Stonepine Capital Management LLC grew its stake in Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after purchasing an additional 175,701 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in Exagen in the fourth quarter valued at about $1,716,000. Kennedy Capital Management LLC grew its stake in Exagen by 8.8% in the fourth quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock valued at $756,000 after purchasing an additional 14,920 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Exagen by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 98,057 shares of the company’s stock valued at $402,000 after purchasing an additional 10,442 shares during the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).